With Carboxylic Acid, Ester Or Metal Salt Thereof Patents (Class 514/163)
  • Patent number: 10254272
    Abstract: The invention, in some aspects, relates to methods for evaluating a human subject for having atherosclerotic coronary artery disease (ASCAD) or as having a coronary atherosclerotic plaque. In some aspects, the invention relates to methods and kits useful for diagnosing, classifying, profiling and treating atherosclerotic CAD and or a coronary atherosclerotic plaque.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: April 9, 2019
    Assignee: Global Genomics Group, LLC
    Inventors: Szilard Voros, Bradley O. Brown, Idean B. Marvasty
  • Patent number: 10098898
    Abstract: Solid oral mesalamine delayed/controlled release tablets with storage stable dissolution profiles are described.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: October 16, 2018
    Assignee: HANDA PHARMACEUTICALS, LLC
    Inventors: K. C. Sung, Chi-Cheng Lin, Chin-Yao Yang, Fang-Yu Liu
  • Patent number: 10052294
    Abstract: Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts of formula (I) and a crystalline form of potassium 2,5-dihydroxybenzenesulfonic acid are provided. Also provided are methods of treating rosacea comprising administering crystalline forms of potassium 2,5-dihydroxybenzenesulfonic acid.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: August 21, 2018
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Unni Santhosh, Annadurai Marimuthu Senthilkumar, Bodireddy Mohan Reddy, Rajendran Kamala, Mahender Rao Siripragada
  • Patent number: 9902681
    Abstract: The invention describes novel mono-hydroxy, di-hydroxy and tri-hydroxy docosapentaenoic acid (DPA) analogs, their preparation, isolation, identification, purification and uses thereof. Resolution of inflammation is now held to be an active process where autacoids promote homeostasis. Using functional-metabololipidomics and in vivo systems, endogenous n-3 docosapentaenoic (DPA) acid is converted during inflammation-resolution in mice and by human leukocytes to novel n-3 products congenerous to D-series resolvins (Rv), protectins (PD) and maresins (MaR), termed specialized pro-resolving mediators (SPM). The new n-3 DPA structures include 7,8,17-trihydroxy-9,11,13,15E, 19Zdocosapentaenoic acid (RvD1n_3 DPA), 7, 14-dihydroxy-8, 10, 12, 16Z, 19Z-docosapentaenoic acid (MaR1n_3 DPA) and related bioactive products.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: February 27, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Jesmond Dalli
  • Patent number: 9782371
    Abstract: A method of preventing or treating a disease associated with demyelination of a nerve cell in a mammal, a method of promoting remyelination or suppressing demyelination of a nerve cell in a mammal, and a method of reducing expression of PMP22 in a nerve cell of a mammal by administration of 2,5-dihydroxybenzenesulfonic acid or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: October 10, 2017
    Assignees: SAMSUNG ELECTRONICS CO., LTD., KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Yunil Lee, Suhyun Kim, Haechul Park, Sangchul Park
  • Patent number: 9713601
    Abstract: The present invention relates to new ingenol derivative compounds for inhibiting cancer cell viability and treating cancer. In other aspects, the invention relates to a pharmaceutical composition, a medicament, methods for treating cancer, and a dosage form.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: July 25, 2017
    Assignee: AMAZÔNIA FITOMEDICAMENTOS LTDA
    Inventors: Luiz Francisco Pianowski, Everardo Ferreira Telles
  • Patent number: 9707185
    Abstract: Nanoparticles with entrapped, nonpolar compounds are disclosed, and a method for their synthesis. The nanoparticles are readily dissolved or dispersed in water. For example, the entrapped nonpolar compounds may include pharmaceutically-active compounds, or natural colorants. The nanoparticles have a nonpolar compound core, an intermediate surfactant layer, and an outer crosslinked polymeric protective layer. In a prototype example, alginic acid nanoparticles were prepared with beta-carotene entrapped in the core, with lecithin as the intermediate surfactant layer. In an alternative embodiment, a layer-by-layer assembly technique may be used to entrap the colorant within nanoparticles.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: July 18, 2017
    Assignee: Board of Supervisors of Louisana State University And Agricultural and Mechanical College
    Inventors: Cristina M. Sabliov, Carlos Ernesto Astete
  • Patent number: 9592216
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: March 14, 2017
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Patent number: 9511044
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: December 6, 2016
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20150148320
    Abstract: Cosmetic compositions comprising salicylic acid derivatives and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. The salicylic acid derivatives are believed to have modulatory activity against one or more biochemical pathways implicated in the appearance of human skin.
    Type: Application
    Filed: March 11, 2014
    Publication date: May 28, 2015
    Applicant: Avon Products, Inc.
    Inventors: Kai Xi, Sung Bin Shin, Hong Hu
  • Publication number: 20150094286
    Abstract: A two-part aqueous composition for treating skin ailments, such as acne vulgaris, includes an acidic part having salicylic acid and an ?-hydroxy acid, and an alkaline part having an alkaline nitrite salt. The ?-hydroxy acid is preferably glycolic acid, lactic acid, malic acid, mandelic acid or a combination thereof. The alkaline nitrite salt is preferably sodium nitrite. The acidic part and the alkaline part are an acidic aqueous solution and an alkaline aqueous solution, respectively, which may either be mixed with one another then applied to an affected portion of a patient's skin or, alternatively, may be sequentially applied to the affected portion of the patient's skin, preferably within 15 minutes of one another.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 2, 2015
    Applicant: KANTIAN SKINCARE LLC
    Inventor: Robert D. Kross
  • Patent number: 8992994
    Abstract: The present invention relates to stable topical pharmaceutical compositions for the treatment of psoriasis. Disclosed are in particular nonoemulsions comprising nano size droplets of one or more anti-psoriasis agents, e.g. clobetasol and/or salicylic acid. These compositions exhibit greater permeability, and improved bioavailability. The invention also relates to processes for the preparation of such compositions.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: March 31, 2015
    Assignee: Cadila Healthcare Limited
    Inventors: Sunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh, Jitendra Dasharathlal Patel, Jinesh Suresh Pancholi
  • Patent number: 8980869
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: March 17, 2015
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventor: Pedro Cuevas Sànchez
  • Publication number: 20150072960
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 12, 2015
    Applicant: Biosuccess Biotech Co. Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Publication number: 20150071874
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 12, 2015
    Applicant: Biosuccess Biotech Co. Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Publication number: 20150038441
    Abstract: The invention relates to a kit-in-part comprising of a composition for the use as a cleaning and treating of ears of a companion animal and suitable packaging material, wherein the kit-in part additionally consists of components selected from the group of a pharmaceutical composition for use in the treatment of otitis externa, application and dosage information, cannules, cotton swabs, gauzes and information about the cleaning and maintenance ears of a companion animal.
    Type: Application
    Filed: December 21, 2011
    Publication date: February 5, 2015
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Joachim Karle, Reinhard Seffner
  • Publication number: 20150005266
    Abstract: The invention provides a topical formulation adapted for treatment of a skin condition comprising (i) at least one retinoid; and (ii) salicylic acid or an ester, amide, salt, or solvate thereof. The invention also includes a kit for treatment of skin conditions comprising a retinoid and salicylic acid, as well as a method of treating skin conditions utilizing the inventive formulation and kit.
    Type: Application
    Filed: September 18, 2014
    Publication date: January 1, 2015
    Inventor: William P. Purcell
  • Patent number: 8921390
    Abstract: A Medicaments for inhibiting thrombus formation contains active ingredients which are triflusal and clopidogrel bisulfate, wherein a mass ratio of triflusal to clopidogrel bisulfate is (100-650):(30-150), preferably (1-20):1, more preferably (3-6):1, and even more preferably 3:1 or 6:1.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: December 30, 2014
    Assignee: Guizhou Liansheng Pharmaceutical Co. Ltd.
    Inventor: Chunhua Su
  • Patent number: 8912171
    Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: December 16, 2014
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventor: Pedro Cuevas Sànchez
  • Publication number: 20140364504
    Abstract: A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.
    Type: Application
    Filed: June 10, 2013
    Publication date: December 11, 2014
    Inventor: Naeem Uddin
  • Publication number: 20140335171
    Abstract: The invention discloses stable formulations of acetylsalicylic acid or salts thereof, omega-3 fatty acids and amylose in soft gelatin capsules.
    Type: Application
    Filed: December 4, 2012
    Publication date: November 13, 2014
    Inventors: Simone Carucci, Alberto Bernareggi, Maurizio Marchiorri, Marco Pontiggia
  • Patent number: 8883767
    Abstract: A low ether gel composition for application to skin comprising a keratolytic agent, in particular salicylic acid, and comprising a nitrocellulose and one or more volatile ingredients, which forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the skin; methods of treating using such compositions, and dispensers containing such compositions.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: November 11, 2014
    Assignee: MSD Consumer Care, Inc.
    Inventors: Gerald R. Dever, Eric Chen-nan Su, William Scott Rogersr, Robert C. Johnson
  • Publication number: 20140322310
    Abstract: Topical gel compositions comprising ingenol-3-angelate, wherein less than 10% of the ingenol-3-angelate degrades when the gel is stored for 2 years at 25° C.
    Type: Application
    Filed: December 12, 2012
    Publication date: October 30, 2014
    Inventors: Per Ola Arvidsson, Edit Farkas, Karsten Petersson, Gert Hoy
  • Publication number: 20140303074
    Abstract: The present disclosure provides methods of reducing immunodeficiency virus transcription, involving use of diflunisal or an active ester thereof. The disclosure also provides methods of treating an immunodeficiency virus infection in an individual, the method generally involving administering to the individual an effective amount of diflunisal or an active ester thereof.
    Type: Application
    Filed: December 12, 2012
    Publication date: October 9, 2014
    Inventors: Eric M. Verdin, Kotaro Shirakawa
  • Patent number: 8834857
    Abstract: A method for cleaning, benefiting, or deodorizing skin or hair utilizing a body wash, skin cleaner, soap, shampoo or deodorizer formulation containing a controlled release skin benefit or deodorizing salt, a hydrophilic moisturizing polymer and surfactants is described. The method imparts benefits or deodorizing agents to the skin or hair and maintains effective levels for an extended period.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: September 16, 2014
    Assignee: Nevada Naturals Inc.
    Inventors: Anthony E. Winston, Richard F. Stockel, Anthony Joseph Sawyer
  • Publication number: 20140256688
    Abstract: A topical anorectal composition includes trimethylsiloxysilicate; at least one surfactant selected from the group consisting of sodium lauryl sulfate, alkyl- and alkoxy-dimethicone copolyol, polysorbate and a combination thereof; a non-polar volatile siloxane solvent; at least 15% (w/w) water; and a pharmaceutical agent selected from the group consisting of pramoxine, phenylephrine, hydrocortisone, salicylic acid, nitroglycerine, sildenafil, or their salts and combinations thereof, wherein the composition is sufficiently designed to dry within 60 seconds after application to the anorectal mucosa to form a dried composition, and wherein the dried composition forms: a flexible film, wherein the flexible film closely follows irregularities of the body surface as well as movement of the body surface, and (ii) a durable film, wherein the durable film does not crack or flake off and remains intact for more than 12 hours giving release of the pharmaceutical agent for an extended period of time.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 11, 2014
    Inventors: Evgenia Lozinsky, Eran Eilat
  • Publication number: 20140249115
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 4, 2014
    Applicant: Jazz Pharmaceuticals, Inc.
    Inventor: Jazz Pharmaceuticals, Inc.
  • Publication number: 20140249490
    Abstract: Methods for prevention or treatment of capsular contracture following surgical implants and other fibrosis related conditions comprising applying a topical composition comprising a pharmaceutically acceptable keratolytic, a pharmaceutically acceptable protein denaturant, a hydrating agent, and combinations thereof are disclosed.
    Type: Application
    Filed: March 4, 2013
    Publication date: September 4, 2014
    Applicant: J&E Solutions, LLC
    Inventors: Jeanne V. FRIEDMAN, Elisa M. Raskin
  • Publication number: 20140242138
    Abstract: Method for the preparation of microencapsulated essential oils or a formulation thereof for various non-agricultural applications.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Applicant: BOTANOCAP LTD.
    Inventors: Amnon Kritzman, Arie Markus, Pnina Strongin, Charles Linder
  • Patent number: 8815836
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: August 26, 2014
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cueva Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20140234420
    Abstract: The present invention describes methods and compositions for treating diverse dermatological conditions, including acne and psoriasis, using zein containing nanocarrier devices for topical delivery of methotrexate, retinoic acid and benzoyl peroxide to select targets in the skin.
    Type: Application
    Filed: August 14, 2013
    Publication date: August 21, 2014
    Inventors: Omathanu P. Perumal, Ranjith Kumar Averineni
  • Publication number: 20140228328
    Abstract: The invention relates to anti-microbial compositions useful against a wide range of microorganisms undesirable on a wide variety of materials, including food, food contact and non-food contact surfaces, and surfaces in industrial, recreational, health care, and other institutional environments. More particularly, the anti-microbial compositions comprise peracetic acid in combination with a) citric acid or a salt and b) salicylic acid or a salt in aqueous solution.
    Type: Application
    Filed: April 18, 2014
    Publication date: August 14, 2014
    Applicant: FMC Corporation
    Inventors: John M. ROVISON, Donald LAPHAM, Shibu ABRAHAM, Mary HOMAN
  • Publication number: 20140219957
    Abstract: The invention features methods of treating an immune disorder characterized by elevated Pin1 marker levels in a subject by administering a retinoic acid compound. Additionally, the invention features methods of treating immune disorders (e.g., immune disorders characterized by elevated Pin1 marker levels) by administering a retinoic acid compound in combination with an anti-inflammatory, anti-viral, or anti-microbial compound.
    Type: Application
    Filed: May 29, 2012
    Publication date: August 7, 2014
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Adrian Tun-Kyi, Greg Finn
  • Publication number: 20140206654
    Abstract: The present invention refers to the use of a compound of Formula (I?) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodysplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (I?) for the treatment and/or prophylaxis of cancer of an organ.
    Type: Application
    Filed: August 12, 2013
    Publication date: July 24, 2014
    Applicant: Action Medicines, S.L.
    Inventors: Pedro Cuevas Sanchez, Guillermo Gimenez Gallego, Inigo Saenz De Tejada Morgan, Javier Angulo Frutos, Rosa Maria Lozano Puerto, Antonio Romero Garrido, Serafin Valverde Lopez
  • Publication number: 20140179645
    Abstract: Described herein are antimicrobial compositions, methods of making thereof, a kit comprising said compositions, and methods for removing microorganisms from surfaces by using said compositions. In one aspect, the antimicrobial composition is a kit composed of a first composition that comprises a dissolved metal salt and a second composition that comprises a ligand, wherein the ligand comprises (i) a residue of antibacterial agent and (ii) a residue of an antifungal agent, wherein the antibacterial agent and/or antifungal agent comprises at least one aryl group. These compositions can further comprise (a) surfactants and/or emulsifiers, (b) thickeners, and (c) solvents or carriers such as water, propylene glycol, and glycerin. In some aspects, these compositions can also comprise fragrances, humectants, emollients, essential oils, plant extracts, and other natural products. Optional additives that are known in the art may also be included.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 26, 2014
    Applicant: THE PISCES GROUP LLC
    Inventor: Douglas Charles Arndt
  • Patent number: 8759325
    Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: June 24, 2014
    Assignee: The Regents of the University of Oklahoma
    Inventor: Richard F. Harty
  • Publication number: 20140155349
    Abstract: The use of a pharmaceutical regimen to deter in an individual, as the individual ages, the development of a cardiovascular disease (CVD) or Alzheimer's disease or to treat an individual who has CVD or Alzheimer's, the individual ingesting on a daily basis a regimen comprising pharmaceutically effective amounts of magnesium salicylate and naproxen, the amount of the magnesium salicylate being no greater than about 260 mg, and also the use of a pharmaceutical regimen to treat an individual who has Type 2 diabetes, the regimen being ingested daily by the individual and comprising pharmaceutically effective amounts of at least one glucose-lowering drug and magnesium salicylate in an amount no greater than about 260 mg.
    Type: Application
    Filed: June 10, 2013
    Publication date: June 5, 2014
    Inventors: Anthony I. Rozmanith, Jolan S. Rozmanith
  • Patent number: 8734838
    Abstract: A pressure-sensitive adhesive composition which comprises three ingredients, i.e., polyisoprene, a styrene/isoprene/styrene copolymer, and solid polyisobutylene, in a proportion of (10-60)/(10-50)/(20-60) by weight and further contains a non-solid isobutylene polymer and a tackifier, characterized in that the amount of the non-solid isobutylene polymer is 1 to 30 pts. wt., excluding 30 pts. wt., per 100 pts. wt. of the sum of the three ingredients, i.e., the polyisoprene, styrene/isoprene/styrene copolymer, and solid polyisobutylene. When used in an adhesive patch for external use on the skin, the composition has satisfactory tackiness regardless of whether the temperature of the surrounding air is high or low, has excellent long-term storage stability, retains the necessary cohesive force, and does not unnecessarily irritate the skin.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: May 27, 2014
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Masato Shirai, Takaaki Yoshinaga, Masato Wakamatsu
  • Publication number: 20140106005
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease. The phorbol esters described are particularly useful in the treatment of neoplastic diseases and/or managing the side effects of chemotherapeutic and radiotherapeutic treatments of neoplastic diseases.
    Type: Application
    Filed: January 18, 2013
    Publication date: April 17, 2014
    Applicant: Biosuccess Biotech Co., Ltd.
    Inventors: Zheng Tao Han, Hung-Fong Chen
  • Publication number: 20140100202
    Abstract: A process is described for the preparation of a composition comprising a metal complex in an oily organic matrix, the latter being at the same time able to promote the formation of the complex. Said process also envisages that the complex, once formed, is not separated from said oily organic matrix, but the resulting composition is used as such, as having observed that the performances of the complex present therein is thus improved.
    Type: Application
    Filed: June 7, 2012
    Publication date: April 10, 2014
    Applicant: VOLARE & CONNECTING, LLC
    Inventor: Giuliano Leonardi
  • Publication number: 20140066414
    Abstract: The invention provides a topical formulation adapted for treatment of a skin condition comprising (i) at least one retinoid; and (ii) salicylic acid or an ester, amide, salt, or solvate thereof. The invention also includes a kit for treatment of skin conditions comprising a retinoid and salicylic acid, as well as a method of treating skin conditions utilizing the inventive formulation and kit.
    Type: Application
    Filed: May 3, 2013
    Publication date: March 6, 2014
    Inventor: William Paul Purcell
  • Publication number: 20140037561
    Abstract: A composition is provided that capitalizes on the biological activity of trichloroacetic acid, but effectively reduces or eliminates TCA induced irritation allowing the composition to be used as a wrinkle effacer or stimulant of skin cell turnover; uses previously thought as commercially impossible with TCA. Also provided are processes of effacing wrinkles or stimulating skin cell turnover including applying the inventive composition to the skin of a subject.
    Type: Application
    Filed: February 3, 2011
    Publication date: February 6, 2014
    Inventors: John E. Kulesza, Mark Rubin
  • Publication number: 20140017194
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS, or the development of neoplasms in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing Th1 cytokine expression, decreasing Th2 cytokine expression, increasing ERK phosphorylation, inducing apoptosis in malignant cells, inducing remission, maintaining remission, as chemotherapeutic agents, as well as for decreasing symptoms of cytopathic diseases and opportunistic infections that may accompany such diseases.
    Type: Application
    Filed: March 11, 2013
    Publication date: January 16, 2014
    Applicant: Biosuccess Biotech Co. Ltd.
    Inventors: Zheng Tao Han, Richard L. Chang
  • Publication number: 20140017196
    Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
    Type: Application
    Filed: September 16, 2013
    Publication date: January 16, 2014
    Applicant: BIOSUCCESS BIOTECH CO., LTD.
    Inventors: Zheng Tao HAN, Hung-Fong CHEN
  • Publication number: 20140018330
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Application
    Filed: July 9, 2013
    Publication date: January 16, 2014
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Patent number: 8629127
    Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: January 14, 2014
    Assignee: The Regents of the University of Oklahoma
    Inventor: Richard F. Harty
  • Patent number: 8623847
    Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
    Type: Grant
    Filed: May 3, 2012
    Date of Patent: January 7, 2014
    Assignee: The Regents of the University of Oklahoma
    Inventor: Richard F. Harty
  • Publication number: 20140005151
    Abstract: Administering water-soluble or dispersible synthetic analogs or derivatives of astaxanthin, lutein, zeaxanthin, or lycophyll and/or other carotenoids to a subject may reduce some of the adverse effects of inflammation in a body organ or tissue. The analogs or derivatives may be incorporated into pharmaceutical, over-the-counter, or nutraceutical preparations. Administration of the analogs or derivatives described herein may reduce deposition of inflammatory mediators such as C-reactive protein, complement system proteins or the membrane attack complex (MAC) in tissues. Reduced deposition of these molecules in tissues may reduce cell damage and/or lysis in the tissues.
    Type: Application
    Filed: June 19, 2013
    Publication date: January 2, 2014
    Inventor: Samuel F. Lockwood
  • Publication number: 20130331362
    Abstract: An ophthalmic solution is provided. The ophthalmic solution includes an ultraviolet-A absorber and an ultraviolet-B absorber. The ophthalmic solution has a viscosity of between about 1 and 100 cps. The ophthalmic solution can be used to absorb ultraviolet radiation in the eye.
    Type: Application
    Filed: June 6, 2012
    Publication date: December 12, 2013
    Inventor: Brian J. Smith
  • Publication number: 20130324502
    Abstract: A dermal, transdermal and/or mucosal formulation for topical application on skin, comprising an active pharmaceutical ingredient and a pharmaceutically acceptable solvent, and an anti-solvent; wherein the active pharmaceutical ingredient is soluble in the solvent in the absence of the anti-solvent, and wherein the active pharmaceutical ingredient is substantially in the solid state in the presence of the anti-solvent. A method for increasing the stability of an active pharmaceutical ingredient.
    Type: Application
    Filed: February 10, 2012
    Publication date: December 5, 2013
    Applicant: MOBERG PHARMA AB
    Inventors: Åke Lindahl, Peter Kaufmann